Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Drops By 40.3%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report) saw a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 34,897 shares, a decrease of 40.3% from the August 15th total of 58,435 shares. Based on an average daily trading volume, of 13,850 shares, the short-interest ratio is currently 2.5 days. Approximately 0.8% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings raised Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cyclacel Pharmaceuticals presently has a consensus rating of “Sell”.

Get Cyclacel Pharmaceuticals alerts:

Check Out Our Latest Report on BGMS

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ:BGMS traded down $0.13 on Wednesday, reaching $0.92. The company’s stock had a trading volume of 21,021 shares, compared to its average volume of 885,222. The company has a 50-day simple moving average of $0.90 and a 200 day simple moving average of $0.94. Cyclacel Pharmaceuticals has a 52-week low of $0.57 and a 52-week high of $6.70. The company has a market cap of $5.09 million, a P/E ratio of -0.26 and a beta of -0.40.

Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.08) EPS for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 118.27% and a negative return on equity of 31.60%. The business had revenue of $0.34 million during the quarter.

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.

Featured Stories

• Five stocks we like better than Cyclacel Pharmaceuticals
• Micron’s AI Memory Boom Could Send Shares 100% Higher
• Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
• The Ultimate Cyber Shield: CrowdStrike Rises Past $235
• Palantir Just Told Wall Street Where AI Infrastructure Is Headed

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.